88 - Thinking Outside the Box: Immunotherapy for Immunocompromised Host

Thursday, October 17, 2024

3:15 PM – 4:30 PM US PT

Location: 502 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Jennifer Cuellar-Rodriguez, MD, FIDSA

Staff Clinician
National Institute of Allergy and infectious Diseases
Bethesda, MD, United States
Donald Vinh, MD

Associate Professor, Senior Clinician-Scientist
McGill University Health Centre
Montreal, QC, Canada

Faculty(s)

Donald Vinh, MD

Associate Professor, Senior Clinician-Scientist
McGill University Health Centre
Montreal, QC, Canada
CZ

Christa Zerbe, MD

MD
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD, United States
Mihai Netea, MD, PhD

Head Division Experimental Internal Medicine
Radboud University Medical Center
Nijmegen, Netherlands

Disclosure(s):

Jennifer Cuellar-Rodriguez, MD, FIDSA: No financial relationships to disclose

Donald Vinh, MD: AstraZeneca: Advisor/Consultant (Terminated, October 24, 2022), Honoraria (Terminated, October 24, 2022); GSK: Board Member (Terminated, May 12, 2022); Merck & Co., Inc.: Board Member (Terminated, January 8, 2024); Moderna, Inc.: Advisor/Consultant (Ongoing); Takeda: Board Member (Ongoing), Honoraria (Ongoing); Xediton: Board Member (Terminated, February 16, 2024)

Christa Zerbe, MD: No financial relationships to disclose

Mihai Netea, MD, PhD: Biotrip: Board Member (Ongoing), Stocks/Bonds (Private Company) (Ongoing); Lemba: Board Member (Ongoing), Stocks/Bonds (Private Company) (Ongoing); Trained Therapeutic: Advisor/Consultant (Ongoing), Patents for modulation of trained immunity (Ongoing), Stocks/Bonds (Private Company) (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify areas where the defective host response can specifically be targeted to treat infectious diseases;
identify host-directed therapeutic strategies for the treatment of viral infections;
identify host-directed therapeutic strategies for the treatment of mycobacterial/fungal infections;
identify host-directed therapeutic strategies for the treatment bacterial infections.

Presentations:

3:15 PM – 3:40 PM US PT

Helping the Host before things Go Viral: Immunotherapy of Viral Infections
Speaker: Donald Vinh, MD – McGill University Health Centre
3:40 PM – 4:05 PM US PT

Immunotherapy for mycobacterial and fungal infections
Speaker: Christa Zerbe, MD – Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
4:05 PM – 4:30 PM US PT

Immunotherapy for bacterial infections
Speaker: Mihai Netea, MD, PhD – Radboud University Medical Center